Home Newsfeeds Identiv Q4 Sales $29.00M Beat $27.87M Estimate

Identiv Q4 Sales $29.00M Beat $27.87M Estimate

Identiv (NASDAQ: INVE) reported quarterly sales of $29.00 million which beat the analyst consensus estimate of $27.87 million by 4.06 percent. This is a 1.70 percent increase over sales of $28.52 million the same period last year.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Identiv (NASDAQ:INVE) reported quarterly sales of $29.00 million which beat the analyst consensus estimate of $27.87 million by 4.06 percent. This is a 1.70 percent increase over sales of $28.52 million the same period last year.

Exela Technologies Announces Public Sector Customer Growth; Signed Several Additional U.S. Counties For Its Digital Mailroom Solution

By Happy Mohamed

July 18, 8:47 AM

Exela Technologies, Inc. ("Exela" or "the Company") (NASDAQ: XELA, XELAP), a leader in business processing automation ("BPA"), announced today that the Company signed several

XELA

Baird Maintains Outperform on Cooper Companies, Lowers Price Target to $355

By Benzinga Newsdesk

December 9, 1:41 PM

Baird analyst Jeff Johnson maintains Cooper Companies (NYSE:COO) with a Outperform and lowers the price target from $370 to $355.

COO

Why Are Pinterest Shares Are Trading Higher On Monday?

By AJ Fabino

March 27, 10:15 AM

Advertisers told analysts at UBS that Pinterest Inc (NYSE: PINS) is taking bolder steps under its new CEO Bill Ready to move more rapidly towards a significant improvement in ad efficacy that could ultimately drive budget and further monetization partnerships, something that UBS took as a cat

PINS

Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3l Ocular For Ophthalmic Applications; Terms Of The Agreement Are Not Disclosed.

By Happy Mohamed

July 27, 9:13 AM

Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC ("Verséa

CELU

Identiv Q4 Sales $29.00M Beat $27.87M Estimate

Related Posts

Exela Technologies Announces Public Sector Customer Growth; Signed Several Additional U.S. Counties For Its Digital Mailroom Solution

Baird Maintains Outperform on Cooper Companies, Lowers Price Target to $355

Why Are Pinterest Shares Are Trading Higher On Monday?

Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3l Ocular For Ophthalmic Applications; Terms Of The Agreement Are Not Disclosed.